Evidence map›Paper›PMID 20102409›Full record

ArticleImmunology2010

Hepcidin messenger RNA expression in human lymphocytes.

Jorge P Pinto, Vera Dias, Heinz Zoller, Graça Porto, Helena Carmo, Félix Carvalho, Maria de Sousa

Open access · greenAbstract read
In one paragraph

Article in Immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 75 citations in OpenAlex.

  1. mBio · 2026
    Article
  2. Article
  3. Hepcidin and Tissue-Specific Iron Regulatory Networks.Advances in experimental medicine and biology · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Hepcidin expression in psoriasis patients.Indian journal of dermatology · 2014
    Article
  15. Distinct patterns of hepcidin and iron regulation during HIV-1, HBV, and HCV infections.Proceedings of the National Academy of Sciences of the United States of America · 2014
    Article
  16. Source of iron overload in multiple sclerosis.Cellular and molecular life sciences : CMLS · 2014
    Article
  17. Article
  18. Review
  19. Article
  20. [Anemia in patients with rheumatoid arthritis].Zeitschrift fur Rheumatologie · 2012
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Jorge P PintoIron Genes and Immune System, IBMC-Instituto de Biologia Molecular e Celular, Universidade do Porto, Porto, Portugal.
Vera Dias
Heinz Zoller
Graça Porto
Helena Carmo
Félix Carvalho
Maria de Sousa
Universidade do Porto · PTHospital de Santo António · PTInnsbruck Medical University · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepcidin regulates intracellular iron levels by interacting with and promoting the degradation of ferroportin, a membrane protein and the only known cellular iron exporter. Studies of hepcidin expression and regulation have focused on its effects in innate immunity and as a regulator of systemic iron metabolism. In the present study we characterized the expression of hepcidin messenger RNA (mRNA) in human peripheral blood mononuclear cells (PBMCs) with a focus on peripheral blood lymphocytes (PBLs). We found that (1) all human PBMCs analyzed express basal hepcidin mRNA levels; (2) hepcidin mRNA expression increases after T-lymphocyte activation; (3) expression by PBLs increases in response to challenge by holotransferrin (Fe-TF) and by ferric citrate in vitro; (4) the Fe-TF-mediated up-regulation of hepcidin decreases ferroportin expression at the cytoplasmic membrane of PBLs; and (5) silencing of tumour necrosis factor-alpha (TNF-alpha) abrogates the effect of Fe-TF. In summary, we show that hepcidin expression determines intracellular iron levels by regulating the expression of ferroportin, as described in other cells, and that inappropriately low expression of hepcidin impairs normal lymphocyte proliferation. The results establish hepcidin as a new player in lymphocyte biology.

Indexed as

AdultAntimicrobial Cationic PeptidesCation Transport ProteinsCell ProliferationFemaleFerric CompoundsFerroportinGene SilencingHepcidinsHumansImmunity, InnateIronLymphocyte ActivationMaleMiddle AgedRNA, MessengerAntimicrobial Cationic PeptidesCation Transport Proteinsferric citrateFerric CompoundsFerroportinHAMP protein, humanHepcidinsholotransferrinIronRNA, MessengerTransferrinTumor Necrosis Factor-alpha

Identifiers

PMID20102409
PMCPMC2878466
OpenAlexW1707148630

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.